Eosinophilic Esophagitis Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)

Eosinophilic Esophagitis Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)

DelveInsight’s, “Eosinophilic Esophagitis Pipeline Insight 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eosinophilic Esophagitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Eosinophilic Esophagitis Pipeline Report

  • DelveInsight’s Eosinophilic Esophagitis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Eosinophilic Esophagitis treatment.
  • The leading companies working in the Eosinophilic Esophagitis Market include AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeutics, EsoCap, Aqilion, Serpin Pharma, and others.
  • Promising Eosinophilic Esophagitis Pipeline Therapies in the various stages of development include Tezepelumab, Etrasimod, Reslizumab, Dupilumab, ESO-101, NDX-3315, and others.
  • January 2024: AstraZeneca announced a study of Phase 3 clinical trials for Tezepelumab. A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
  • January 2024: Eliodi Pharmaceuticals announced a study of Phase 3 clinical trials for APT-1011. This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension. This study will evaluate the efficacy and safety of APT-1011 3 mg administered HS (hora somni, at bedtime) for the induction of response to treatment (symptomatic and histologic) over 24 weeks. The open-label extension will continue to evaluate long-term safety in subjects who consent to continue on open-label treatment with APT-1011.
  • January 2024: Celldex Therapeutics announced a study of Phase 2 clinical trials for barzolvolimab. The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.

 

Request a sample and discover the recent advances in Eosinophilic Esophagitis Treatment Drugs @ Eosinophilic Esophagitis Pipeline Report

 

In the Eosinophilic Esophagitis pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Eosinophilic Esophagitis Overview

Eosinophilic Esophagitis (EoE) is a chronic inflammatory condition of the esophagus characterized by the presence of an elevated number of eosinophils, a type of white blood cell, in the lining of the esophagus. Eosinophils are typically associated with allergic responses and immune reactions. In the case of EoE, their accumulation in the esophagus can lead to inflammation, tissue damage, and various symptoms.

 

Find out more about Eosinophilic Esophagitis Therapeutics Assessment @ Eosinophilic Esophagitis Preclinical and Discovery Stage Products

 

Eosinophilic Esophagitis Emerging Drugs Profile

  • APT-1011: Ellodi Pharmaceuticals. 

 

DelveInsight’s Eosinophilic Esophagitis Pipeline Report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Eosinophilic Esophagitis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

 

Eosinophilic Esophagitis Pipeline Products have been categorized under various Molecule types such as

  • Peptide
  • Protein
  • Propylene glycols
  • Cell Therapy

 

Eosinophilic Esophagitis Pipeline Therapeutics Assessment

There are approx. 18+ Eosinophilic Esophagitis companies which are developing the Eosinophilic Esophagitis therapies. The Eosinophilic Esophagitis companies which have their Eosinophilic Esophagitis drug candidates in the most advanced stage, i.e. Phase III include, Ellodi Pharmaceuticals.

 

Learn more about the emerging Eosinophilic Esophagitis Pipeline Therapies @ Eosinophilic Esophagitis Clinical Trials Assessment

 

Scope of the Eosinophilic Esophagitis Pipeline Report

  • Coverage- Global
  • Eosinophilic Esophagitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Eosinophilic Esophagitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Eosinophilic Esophagitis Companies- AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeutics, EsoCap, Aqilion, Serpin Pharma, and others.
  • Eosinophilic Esophagitis Pipeline Therapies- Tezepelumab, Etrasimod, Reslizumab, Dupilumab, ESO-101, NDX-3315, and others.

 

Dive deep into rich insights for new drugs for Eosinophilic Esophagitis Treatment, Visit @ Eosinophilic Esophagitis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Eosinophilic Esophagitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Eosinophilic Esophagitis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Benralizumab: AstraZeneca
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. IRL201104: Revolo Biotherapeutics
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. Mometasone: EsoCap
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. AQ280: Aqilion
  18. Drug profiles in the detailed report…..
  19. Preclinical and Discovery Stage Products
  20. SP 16: Serpin Pharma
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Eosinophilic Esophagitis Key Companies
  24. Eosinophilic Esophagitis Key Products
  25. Eosinophilic Esophagitis- Unmet Needs
  26. Eosinophilic Esophagitis- Market Drivers and Barriers
  27. Eosinophilic Esophagitis- Future Perspectives and Conclusion
  28. Eosinophilic Esophagitis Analyst Views
  29. Eosinophilic Esophagitis Key Companies
  30. Appendix

 

For further information on the Eosinophilic Esophagitis Pipeline therapeutics, reach out to Eosinophilic Esophagitis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting